{
    "clinical_study": {
        "@rank": "153159", 
        "arm_group": [
            {
                "arm_group_label": "Vancomycin", 
                "description": "Vancomycin"
            }, 
            {
                "arm_group_label": "Linezolid", 
                "description": "Linezolid"
            }
        ], 
        "biospec_descr": {
            "textblock": "urine"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "Acute renal injury is a common complication of critical illness. Drug induced renal insult\n      compounds the degree of injury in many patients, and a great deal of research has focused on\n      prevention of this complication. Traditional biomarkers of renal injury like serum\n      creatinine and blood urea nitrogen content fail to consistently predict harm among patients\n      at risk. Kidney Injury Molecule 1 (KIM-1) will be studied as a biomarker of renal injury."
        }, 
        "brief_title": "Urinary KIM-1 After Vancomycin or Linezolid Administration", 
        "completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Acute Kidney Injury", 
        "condition_browse": {
            "mesh_term": [
                "Acute Kidney Injury", 
                "Wounds and Injuries"
            ]
        }, 
        "detailed_description": {
            "textblock": "see above"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Eligible patients are male or female adults \u226518 years of age with an expected\n             hospital stay of at least 48 hours.\n\n          -  Eligible patients are already prescribed intravenous vancomycin or linezolid per\n             their primary care providers as a standard of care and dosed in manner that is\n             consistent with current institutional practices. Receipt of these antibiotics is not\n             investigational.\n\n        Exclusion Criteria:\n\n          -  Exclusion criteria will include patients who have stage 3or greater Chronic Kidney\n             Disease or who have acute kidney injury prior to the start of intravenous vancomycin\n             therapy, patients that only receive one dose of IV vancomycin or linezolid in total,\n             as well as patients with potentially altered pharmacokinetic parameters (pregnant\n             patients, burn patients, and those that are morbidly obese (BMI \u2265 40 kg/m2).\n\n          -  Additionally, patients will be excluded if they are to receive more than 1 concurrent\n             nephrotoxic medication within the prior 72 hours, have received intravenous contrast\n             within 120 hours before randomization, exhibit baseline hematuria, or baseline\n             proteinuria.\n\n          -  A list of concurrent nephrotoxins that would exclude patients from the study is\n             provided in Appendix C.\n\n          -  Age Range:  \u226518 years of age, if age > 90 will report as > 90 years"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Critically/Terminally Ill (ER, ICU)"
            }
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02067390", 
            "org_study_id": "STU00075251"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Vancomycin", 
                "Linezolid"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 18, 2014", 
        "location": {
            "contact": {
                "email": "mscheetz@nmh.org", 
                "last_name": "Scheetz"
            }, 
            "facility": {
                "address": {
                    "city": "Chicago", 
                    "country": "United States", 
                    "state": "Illinois", 
                    "zip": "60611"
                }, 
                "name": "Northwestern Medicine"
            }, 
            "investigator": {
                "last_name": "Marc H Scheetz, PharmD, MSc", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "official_title": "Novel Urinary Biomarkers in the Detection of Vancomycin Associated Renal Injury", 
        "overall_contact": {
            "email": "mscheetz@nmh.org", 
            "last_name": "Marc Scheetz, PharmD, MSc", 
            "phone": "312.926.2546"
        }, 
        "overall_contact_backup": {
            "email": "nrhodes@nmh.org", 
            "last_name": "N. J Rhodes, PharmD", 
            "phone": "312.926.8689"
        }, 
        "overall_official": {
            "affiliation": "Northwestern Memorial Hospital / Midwestern University", 
            "last_name": "Marc H Scheetz, PharmD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Urinary KIM-1 concentrations will be compared between patients receiving vancomycin and linezolid", 
            "measure": "Urinary KIM-1 concentrations", 
            "safety_issue": "Yes", 
            "time_frame": "Urinary levels from day -1 to day +5, clinical outcomes and variables followed for duration of hospitalization"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02067390"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Midwestern University", 
            "investigator_full_name": "Marc Scheetz", 
            "investigator_title": "Associate Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Midwestern University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Midwestern University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "February 2014"
    }
}